title: Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma.
abstract: OBJECTIVE
  Adenocarcinomas may arise primarily from the urinary bladder, but secondary involvement from adenocarcinomas arising in adjacent organs is more common. In the present study we tried to differentiate primary urinary bladder adenocarcinomas from adenocarcinomas arising from the surrounding organs, based on their antigen profiles in routinely processed, paraffin-embedded tissue specimens. We analysed the staining results using stepwise linear discriminant analysis.
  
  
  RESULTS
  We investigated the usefulness of a panel of antibodies against cytokeratin 7, E48, cytokeratin 20, PSA, PSAP, CEA, vimentin, OC125 and HER-2/neu, to discriminate primary bladder adenocarcinoma from adenocarcinomas arising from the prostate, urachus, colon, cervix, ovary and endometrium. In the differential diagnosis with urinary bladder adenocarcinoma, an overall correct classification was reached for 77% and 81% of urachal and colonic carcinomas, respectively, using CEA, for 93% of prostatic adenocarcinomas using PSA, for 82% and 70% of cervical and ovarian adenocarcinomas, respectively, using OC125, and for 91% of endometrial adenocarcinomas using vimentin. Adding other antibodies did not improve the classification results for any of these differential diagnoses.
  
  
  CONCLUSIONS
  For the surgical pathologist, a panel of antibodies consisting of CEA, PSA, OC125 and vimentin is helpful to differentiate primary urinary bladder adenocarcinomas from adenocarcinomas originating from prostate and endometrium, less helpful in differentiation with urachal carcinoma, and not helpful in differentiation with colonic, cervical and ovarian carcinoma.
authors.affiliation: Department of Pathology, Free University Hospital, Amsterdam, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Torenbeek
authors.forename: J H
authors.initials: JH
authors.lastname: Lagendijk
authors.forename: P J
authors.initials: PJ
authors.lastname: Van Diest
authors.forename: H
authors.initials: H
authors.lastname: Bril
authors.forename: F J
authors.initials: FJ
authors.lastname: van de Molengraft
authors.forename: C J
authors.initials: CJ
authors.lastname: Meijer
mesh_terms: D000008:Abdominal Neoplasms / Q000737:chemistry / Q000473:pathology; D000135:Acid Phosphatase / Q000032:analysis / Q000276:immunology; D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology* / Q000556:secondary*; D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000276:immunology; D000918:Antibody Specificity; D018394:CA-125 Antigen / Q000032:analysis / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000032:analysis / Q000276:immunology; D002291:Carcinoma, Papillary / Q000737:chemistry / Q000473:pathology* / Q000556:secondary*; D015815:Cell Adhesion Molecules / Q000032:analysis / Q000276:immunology; D003937:Diagnosis, Differential; D016889:Endometrial Neoplasms / Q000737:chemistry / Q000473:pathology; D005260:Female; D058851:GPI-Linked Proteins; D006023:Glycoproteins / Q000032:analysis / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D007381:Intermediate Filament Proteins / Q000032:analysis / Q000276:immunology; D053554:Keratin-20; D053552:Keratin-7; D007633:Keratins / Q000032:analysis / Q000276:immunology; D008297:Male; D009382:Neoplasms, Unknown Primary / Q000737:chemistry / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000737:chemistry / Q000473:pathology; D011467:Prostate / Q000737:chemistry / Q000201:enzymology; D017430:Prostate-Specific Antigen / Q000032:analysis / Q000276:immunology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000276:immunology; D014497:Urachus / Q000737:chemistry / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000556:secondary*; D002583:Uterine Cervical Neoplasms / Q000737:chemistry / Q000473:pathology; D014746:Vimentin / Q000032:analysis / Q000276:immunology
chemical_list: D000135:Acid Phosphatase; D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen; D002272:Carcinoembryonic Antigen; D015815:Cell Adhesion Molecules; D058851:GPI-Linked Proteins; D006023:Glycoproteins; D007381:Intermediate Filament Proteins; D053554:Keratin-20; D053552:Keratin-7; D007633:Keratins; D017430:Prostate-Specific Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D014746:Vimentin; C507499:KRT20 protein, human; C507497:KRT7 protein, human; C094237:LY6D protein, human